
Parkinson Disease
Latest News

Video Series

Latest Videos
Podcasts
CME Content
More News

AbbVie’s application to the FDA for its selective dopamine D1/D5 receptor partial agonist is supported by data from the phase 3 TEMPO study program.

A recent study demonstrated that distinct aquaporin-4 changes in neuronal and glial synucleinopathies reflect different pathomechanisms and may warrant further investigation.

A recent trial shows that 3 infusions of stem cells significantly enhance motor function in Parkinson patients, highlighting the need for further research.

A recent Canadian study reported similar trends in polysomnography and positive airway pressure initiation over a decade between patients with Parkinson disease and matched controls.

Experts shared their clinical perspectives on trending topics in the treatment and management of movement disorders at the 4th Annual Advanced Therapeutics in Movement and Related Disorders (ATMRD) Congress.

At the 2025 ATMRD Congress, Anissa Mitchell, LCSW, chief program officer at PMD Alliance, discussed immersive, patient-focused sessions aimed at improving clinicians’ empathy, communication, and understanding of Parkinson disease and related disorders.

The medical director of CNS clinical cevelopment at AskBio discussed long-term data presented at ATMRD from the company’s phase 1b trial assessing the investigational gene therapy AB-1005 in Parkinson disease. [WATCH TIME: 6 minutes]

The advisory board member of the Parkinson's Foundation shared personal insights on how love, present-moment awareness, and hope shaped her approach to living with the Parkinson disease. [WATCH TIME: 6 minutes]

A recent study uncovered existing medications that may lower mortality risk in patients with Parkinson disease, suggesting potential for repurposing in future trials.

Findings from a recently published study may offer clinicians a deeper understanding of the complex relationship between Parkinson disease biology and social or environmental factors.

The chief program officer at PMD Alliance described an interactive program designed to help health care providers better understand the lived experience of patients with Parkinson disease and related movement disorders. [WATCH TIME: 6 minutes]

A duo of experts discussed a novel hybrid trial approach combining in-home video assessments with traditional visits to improve Parkinson disease research participation and assess a new investigational therapy. [WATCH TIME: 7 minutes]

Findings revealed that dry mouth and falls were reported more frequently in patients with Parkinson disease treated with solifenacin in comparison with pelvic floor muscle exercise-based behavioral therapy.

A study links high ultraprocessed food consumption to increased risks of nonmotor Parkinson's disease symptoms, highlighting potential dietary impacts on neurodegeneration.

The professor of neurological surgery at Weill Cornell Medicine shared his reaction to the recent approval of the Exablate Neuro platform that uses MRI-guided focused ultrasound to treat Parkinson disease. [WATCH TIME: 5 minutes]

A groundbreaking trial reveals that subthalamic deep brain stimulation effectively treats isolated dystonia, showing significant long-term motor and mental health improvements.

The movement disorder specialist and patient living with Parkinson disease highlighted the need for a more human-centered approach in managing chronic and progressive movement disorders. [WATCH TIME: 6 minutes]

The neuropsychiatry researcher at King's College London highlighted significant gender differences in anxiety, depression, quality of life, and social support among patients with PD undergoing deep brain stimulation. [WATCH TIME: 5 minutes]

Exablate Neuro is a noninvasive, MRI-guided focused ultrasound technology designed to treat targeted brain areas without incisions or implanted hardware, offering a lower-risk alternative to traditional surgery.

Laren Becker, MD, PhD, a physician-scientist at Stanford University, discussed how gastrointestinal dysfunction and peripheral dopaminergic activity impact Parkinson disease treatment and progression.

Continuous subcutaneous apomorphine infusion significantly reduces OFF episodes and enhances ON time in Parkinson's disease patients, improving overall health status.

Research reveals that delayed-release amantadine significantly reduces Parkinson disease symptoms and medication use, offering patients improved quality of life.

A physician assistant specializing in Parkinson disease shared key clinical considerations for selecting and educating patients about on-demand therapies for the movement disorder.

At ATMRD 2025, a patient advocate living with PD and advisory board member of the Parkinson's Foundation outlined key nonpharmacologic tools that have supported her care journey. [WATCH TIME: 5 minutes]

The neurologist at Christiana Care discussed how focused ultrasound may be emerging as a preferred, less invasive treatment option for essential tremor, especially in older patients with comorbidities. [WATCH TIME: 5 minutes]